Moreover, in some cases of advanced thyroid cancer, PD-L1 might be co-expressed with BRAFV600E and TERT promoter mutations, information that might have important consequences on patient prognosis and the possibility of using target therapies [38]. This evidence concerns the gene TERT and thyroid cancer.